Immediate Impact
1 by Nobel laureates 52 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of Antoine Khalil being referenced
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
2022
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Antoine Khalil | 1193 | 684 | 310 | 106 | 1.8k | |
| Repke J. Snijder | 1504 | 1113 | 410 | 86 | 2.4k | |
| David N. Korones | 394 | 848 | 256 | 87 | 1.8k | |
| Holger Hof | 1242 | 333 | 370 | 52 | 2.2k | |
| Stephanie A. Terezakis | 613 | 403 | 337 | 122 | 1.8k | |
| James G. Schwade | 840 | 355 | 546 | 74 | 2.1k | |
| Jean‐Léon Lagrange | 1384 | 257 | 565 | 75 | 2.6k | |
| Philip Stanley | 587 | 917 | 537 | 55 | 1.9k | |
| M. Balducci | 972 | 628 | 591 | 132 | 2.3k | |
| Toshiyuki Okumura | 1048 | 165 | 497 | 126 | 1.7k | |
| Ethan B. Ludmir | 700 | 191 | 557 | 189 | 2.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...